1Yessi Octavianti, 2Delfitri Munir, 3Titiek Sumarawati
1,2,3Faculty of Medicine, Sultan Agung Islamic University, St Kaligawe KM 4 Semarang 50012, Indonesia
DOI : https://doi.org/10.47191/ijmra/v7-i01-04Google Scholar Download Pdf
ABSTRACT:
Polycystic Ovary Syndrome (PCOS) is an endocrine and metabolic syndrome characterized by a chronic inflammation and an increase of androgen production in ovarian theca cells.1 The expression of the p65 gene and TNF-α was found to be intracellular inflammation markers in PCOS patients. Previous studies have indicated that the Secretome of hypoxia mesenchymal stem cells (SH-MSCs) has anti-inflammatory properties and is widely reported to be effective in treating various diseases. An experimental study by using the Post Test Only Control Group Design method. This study involved 24 female wistar rats divided into 4 groups. Group K1 consisted of healthy rats, K2 PCOS rats without any treatment, K3 PCOS rats treated with 200μL dose of SH-MSCs, and K4 PCOS rats treated with 400μL dose of SH-MSCs. On the 33rd day, the rats underwent an examination of the p65 and TNF-α gene expression. The result of Shapiro-Wilk test and Levene test indicated that the data were normally distributed and homogenous. In One-Way ANOVA test, groups K III and K IV of PCOS rats showed significantly lower changes in the expression of the p65 and TNF-α genes compared to the control group (p<0.05). The result of Kruskal-Wallis test and Mann-Whitney test showed significant differences in TNF-α gene expression among the groups (p <0.05). While, the post hoc Tamhane test showed significant differences in p65 gene expression among the groups (p<0.05). SH-MSCs given at a dose of 200 µL/kgBW and 400 µL/kgBW had an effect in reducing the expression of the p65 gene and TNF-α gene on female wistar rats of PCOS model.
KEYWORDS:PCOS, P65, SH-MSCs, TNF-α, Gene Expression
REFERENCES1) Chugh RM, Park H soo, El Andaloussi A, et al. Mesenchymal stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin 10. Stem Cell Res Ther 2021;12(1):1–19; doi: 10.1186/s13287-021-02472-w.
2) Dokuzeylül Güngör N, Güngör K, Yurci A, et al. Ovarian drilling down-regulates endometrial nuclear factor-κB p65 expression in women with PCOS: A prospective case-control study. Journal of Turkish Society of Obstetric and Gynecology 2022;19(1):45–50; doi: 10.4274/tjod.galenos.2022.44845
3) Garg R, Rautela J, Dobhal K, et al. An Overview Polycystic Ovary Syndrome -Causes , Pathophysiology. 2023;(May)
4) Abdalla MA, Deshmukh H. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. 2020;1–19; doi: 10.1177/2042018820938305
5) Bulsara J, Patel P, Soni A, et al. A review: Brief insight into Polycystic Ovarian syndrome. Endocrine and Metabolic Science 2021;3(February):100085; doi: 10.1016/j.endmts.2021.100085.
6) Xue M, Zhang X, Chen J, et al. Mesenchymal Stem Cell-Secreted TGF-β1 Restores Treg/Th17 Skewing Induced by Lipopolysaccharide and Hypoxia Challenge via miR-155 Suppression. Najimi M. ed. Stem Cells Int 2022;2022:1–14; doi: 10.1155/2022/5522828.
7) Putra A, Widyatmoko A, Ibrahim S, et al. Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia. F1000Res 2021;10:1–19; doi: 10.12688/f1000research.51191.3.
8) Physiology G. TNF- α haplotype association with polycystic ovary syndrome – a South Indian study. 2013;1493–1503; doi: 10.1007/s10815-013-0080-4.
9) Sazli BI, Lindarto D, Hasan R, et al. Secretome of Hypoxia- Preconditioned Mesenchymal Stem Cells Enhance Angiogenesis in Diabetic Rats with Peripheral Artery Disease. 2023;77(2):90–96; doi: 10.5455/medarh.2023.77.90-96
10) Zhao Y, Pan S, Wu X. Human umbilical cord mesenchymal stem cell-derived exosomes inhibit ovarian granulosa cells inflammatory response through inhibition of NF-κB signaling in polycystic ovary syndrome. J Reprod Immunol 2022;152:103638; doi: 10.1016/j.jri.2022.103638.
11) Wilson EB, Kidani Y, Elsaesser H, et al. NIH Public Access. 2013;11(5):481–491; doi:
10.1016/j.chom.2012.03.009.Emergence.
12) Mühl H, Dhingra S, Booz GW, et al. IL-10/STAT3/SOCS3 Axis Is Involved in the Anti-inflammatory Effect of Benznidazole. Frontiers in Immunology | www.frontiersin.org 2019;1:1267; doi: 10.3389/fimmu.2019.01267
13) Baiu D, Merriam F, Odorico J. Potential Pathways to Restore β-Cell Mass: Pluripotent Stem Cells, Reprogramming, and Endogenous Regeneration. Curr Diab Rep 2011;11(5):392–401; doi: 10.1007/s11892-011-0218-7.
14) Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10(3):170–181; doi: 10.1038/nri2711
Volume 07 Issue 01 January 2024
There is an Open Access article, distributed under the term of the Creative Commons Attribution – Non Commercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits remixing, adapting and building upon the work for non-commercial use, provided the original work is properly cited.
Our Services and Policies
Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected.
The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.
International Journal of Multidisciplinary Research and Analysis will publish 12 monthly online issues per year,IJMRA publishes articles as soon as the final copy-edited version is approved. IJMRA publishes articles and review papers of all subjects area.
Open access is a mechanism by which research outputs are distributed online, Hybrid open access journals, contain a mixture of open access articles and closed access articles.
International Journal of Multidisciplinary Research and Analysis initiate a call for research paper for Volume 07 Issue 12 (December 2024).
PUBLICATION DATES:
1) Last Date of Submission : 26 December 2024 .
2) Article published within a week.
3) Submit Article : editor@ijmra.in or Online
Why with us
1 : IJMRA only accepts original and high quality research and technical papers.
2 : Paper will publish immediately in current issue after registration.
3 : Authors can download their full papers at any time with digital certificate.
The Editors reserve the right to reject papers without sending them out for review.
Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected. The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.